CMS certification 190041
CHRISTUS Shreveport-Bossier Health System
1453 E Bert Kouns Industrial Drive, Shreveport, LA 71105
CHRISTUS Shreveport-Bossier Health System has a CMS overall rating of 3 out of 5 stars. 71% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 26 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 3 and worse on 2. Emergency patients spend a median of 2 h 45 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 479 completed surveys, 20% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | LA | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 381 visits sampled · US median for EDs of the same volume: 3 h 22 min | 2 h 45 min | 2 h 9 min | 2 h 42 min |
| Left before being seen Lower is better · 49,340 patients | 2% | 2% | 2% |
| Stroke symptoms: brain scan read within 45 minutes Higher is better · 11 patients | 36% | 70% | 69% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 87 patients | 68% | 69% | 65% |
How CHRISTUS Shreveport-Bossier Health System compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| CHRISTUS Shreveport-Bossier Health SystemThis hospital | 3/5 | 71% | 2 h 45 min | 3 better 2 worse |
| Willis Knighton Medical CenterSame city | 3/5 | 72% | 2 h 57 min | 2 better 1 worse |
| Ochsner LSU Health Shreveport-St Mary Medical CentSame city | 2/5 | 75% | — | 1 better |
| Overton Brooks VA Medical Center (shreveport)Same city | 2/5 | 67% | — | 2 worse |
| Specialists Hospital ShreveportSame city | Not rated | 82% | — | 1 better |
| Ochsner LSU Health ShreveportSame city | 2/5 | 69% | 4 h 7 min | 4 better |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Shreveport.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 2,859 cases | Too few cases | 4.5% | 3.9% |
| Heart attack 167 cases | Too few cases | 11.5% | 11.9% |
| Heart failure 566 cases | Too few cases | 13% | 11.1% |
| Pneumonia 469 cases | Too few cases | 15% | 15.2% |
| Stroke 176 cases | Too few cases | 11.3% | 11.9% |
| COPD 150 cases | Too few cases | 9.2% | 8.6% |
| Heart bypass surgery (CABG) 134 cases | Too few cases | 2.2% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1 likely 0.69 – 1.32 | 1 |
| After hip or knee replacement 49 cases | Too few cases | 4.4% | 4.1% |
| Deaths after a serious but treatable surgical complication 57 cases | No different | 165.54 per 1,000 likely 108.82 per 1,000 – 222.26 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 4,928 cases | No different | 0.43 per 1,000 likely 0 per 1,000 – 1.18 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 6,646 cases | No different | 0.26 per 1,000 likely 0.06 per 1,000 – 0.47 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 6,951 cases | No different | 0.26 per 1,000 likely 0.06 per 1,000 – 0.45 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 1,482 cases | No different | 2.63 per 1,000 likely 1.17 per 1,000 – 4.1 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 749 cases | No different | 1.56 per 1,000 likely 0.08 per 1,000 – 3.04 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 786 cases | No different | 12.54 per 1,000 likely 6.99 per 1,000 – 18.09 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 1,590 cases | No different | 2.24 per 1,000 likely 0.12 per 1,000 – 4.35 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 751 cases | No different | 5.96 per 1,000 likely 2.44 per 1,000 – 9.49 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 280 cases | No different | 1.66 per 1,000 likely 0.17 per 1,000 – 3.15 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 1,033 cases | No different | 1.29 per 1,000 likely 0.32 per 1,000 – 2.25 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | Better | 0.17 likely 0.01 – 0.85 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0 | 1 |
| Surgical site infections after colon surgery | No different | 0 | 1 |
| MRSA bloodstream infections | No different | 0.72 likely 0.18 – 1.95 | 1 |
| C. diff intestinal infections | Better | 0.03 likely 0 – 0.16 | 1 |
1 more measure had too few cases here to report.
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 272 cases | Too few cases | 13.1% | 14.4% |
| Readmitted after heart failure 796 cases | Too few cases | 23.3% | 21.3% |
| Readmitted after pneumonia 616 cases | Too few cases | 17.7% | 17.3% |
| Readmitted after COPD 207 cases | Too few cases | 19.5% | 20% |
| Readmitted after heart bypass surgery 151 cases | Too few cases | 11.8% | 11% |
| Readmitted after hip or knee replacement 40 cases | Too few cases | 5.7% | 5.8% |
| Days back in hospital after a heart attack 188 cases | Too few cases | 22.7 days per 100 | — |
| Days back in hospital after heart failure 674 cases | Too few cases | 9.3 days per 100 | — |
| Days back in hospital after pneumonia 515 cases | Too few cases | 17.7 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 625 cases | No different | 13.2 per 1,000 likely 10.1 per 1,000 – 17.5 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 170 cases | No different | 11.5 per 100 likely 8.8 per 100 – 14.7 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 170 cases | No different | 5.4 per 100 likely 3.8 per 100 – 7.6 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 444 cases | No different | 1 likely 0.7 – 1.3 | — |
1 more measure had too few cases here to report.
Clinicians registered at this address
62 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Acute Care | 6 |
| Cardiovascular Disease | 6 |
| Internal Medicine | 6 |
| Diagnostic Radiology | 5 |
| Interventional Cardiology | 5 |
| Physician Assistant | 5 |
| Nurse Anesthetist, Certified Registered | 4 |
| Thoracic Surgery (Cardiothoracic Vascular Surgery) | 4 |
| Registered Nurse | 3 |
| Clinical Cardiac Electrophysiology | 2 |
| Family | 2 |
| Nurse Practitioner | 2 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $56,964
- 2020 $73,469
- 2021 $347,150
- 2022 $46,580
- 2023 $132,885
- 2024 $127,029
- 2025 $136,415
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Debt forgiveness | $234 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Merck Sharp & Dohme LLC | $61,306 | 5 |
| BeOne Medicines USA, Inc. | $57,325 | 7 |
| Amgen Inc. | $7,734 | 4 |
| Regeneron Pharmaceuticals, Inc. | $7,141 | 6 |
| E.R. Squibb & Sons, L.L.C. | $1,368 | 1 |
| AstraZeneca Pharmaceuticals LP | $1,300 | 1 |
| Immucor, Inc. | $234 | 1 |
| AstraZeneca UK Limited | $8 | 1 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patient… BeOne Medicines USA, Inc. · NCT05100862 | $57,325 |
| A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positiv… Merck Sharp & Dohme LLC | $38,482 |
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment o… Merck Sharp & Dohme LLC | $22,823 |
| CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY Regeneron Pharmaceuticals, Inc. · NCT03836105 | $7,141 |
| RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Pati… Amgen Inc. | $4,100 |
| PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Pat… Amgen Inc. | $3,634 |
| Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice E.R. Squibb & Sons, L.L.C. · NCT02847728 | $1,368 |
| A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for th… AstraZeneca Pharmaceuticals LP | $1,300 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about CHRISTUS Shreveport-Bossier Health System
Is CHRISTUS Shreveport-Bossier Health System a good hospital?
CHRISTUS Shreveport-Bossier Health System has a CMS overall rating of 3 out of 5 stars. Of the 26 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 3 and worse on 2. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend CHRISTUS Shreveport-Bossier Health System?
71% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 479 completed HCAHPS surveys.
How long is the wait in the CHRISTUS Shreveport-Bossier Health System emergency room?
Emergency patients spend a median of 2 h 45 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with high patient volume, like this one, the median is 3 h 22 min. 2% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does CHRISTUS Shreveport-Bossier Health System receive money from drug and device companies?
Drug and device makers reported $136,415 in payments to CHRISTUS Shreveport-Bossier Health System for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.